It has been reported that US Food and Drug Administration (FDA) on Friday approved Lynparza capsules as the first monotherapy for women with advanced ovarian cancer associated with defective BRCA genes.
FDA approved Lynparza with a genetic test called BRACAnalysis CDx, a companion diagnostic that will help to detect mutations in the BRCA genes (gBRCAm) in blood samples from patients with ovarian cancer.
Read more